. Mean dose (mg/kg) versus dose-normalized AUC (g·min/mL) of tofacitinib in Sprague-Dawley rats after (A) 1-min intravenous infusion of 5 (n = 9), 10 (n = 8), 20 (n = 7), and 50 (n = 7) mg/kg tofacitinib and (B) oral administration of 10 (n = 7), 20 (n = 8), 50 (n = 9), and 100 (n = 7) mg/kg tofacitinib. Bars represent standard deviations (SD). (A) 20 mg/kg was significantly different (p < 0.05) from5 mg/kg. 50 mg/kg was significantly different (p < 0.001) from 5, 10 and 20 mg/kg. (B) 10 mg/kg was significantly different (p < 0.05) from 50mg/kg. 100 mg/kg was significantly different from 10 (p < 0.001), 20 (p < 0.001) and 50 (p < 0.01) mg/kg, respectively. Figure S2 . Plots of dose versus AUC of tofacitinib in Sprague-Dawley rats after (A) 1-min intravenous infusion of 5, 10, 20, and 50 mg/kg tofacitinib and (B) oral administration of 10, 20, 50, and 100 mg/kg tofacitinib. Dose and AUC ratios were calculated based on 5 and 10 mg/kg dose and respective AUC for intravenous and oral administration, respectively.
. Plots of dose versus AUC of tofacitinib in Sprague-Dawley rats after (A) 1-min intravenous infusion of 5, 10, 20, and 50 mg/kg tofacitinib and (B) oral administration of 10, 20, 50, and 100 mg/kg tofacitinib. Dose and AUC ratios were calculated based on 5 and 10 mg/kg dose and respective AUC for intravenous and oral administration, respectively.
